Posted by:
Vincente Tennerelli
The California Office of Health Care Affordability (“OHCA”) has, for the first time, required a Cost and Market Impact Review (“CMIR”) under SB 184, which requires certain health care entities to provide OHCA with prior notice of certain “Material Change Transactions” closing after April 1, 2024. OHCA assesses these transactions for their possible negative impacts on health care access, quality, affordability, and competition. OHCA can conduct a CMIR when it determines a transaction may negatively impact health care access, costs, competition (including competition for labor), or quality. The CMIR process can further delay the closing of the transaction, and a negative CMIR can imperil the transaction altogether.
Since OHCA’s final SB 184 regulations went into effect, OHCA has received 23 pre-transaction notices and had, until June of this year, never determined that a CMIR was necessary. Now, however, OHCA has determined that a subset of a proposed transfer of the assets and operations of 22 skilled nursing facilities from Covenant Care LLC to affiliates of The Ensign Group, Inc., Links Healthcare Group, International Equity Partners, and Spyglass Healthcare warrants a CMIR. The CMIR will relate only to the transfer of operations of three Southern California SNFs to Ensign; OHCA waived the CMIR as to the remaining 19 SNFs. Covenant Care appealed the decision to the Director of the California Department of Health Care Access and Information, but the Director upheld OHCA’s determination eight days later. OHCA anticipates releasing a preliminary CMIR on September 22, 2025, after which the parties and the public will have ten days to comment before OHCA issues its final CMIR. The parties will then have to wait an additional 60 days to close, though proceeding with the transaction in the face of a negative CMIR could prompt regulatory action.